Your first paycheck in medical device sales might not be what you expected.
Understanding how commission structures, W2 versus 1099, and direct versus distributor roles actually work could be the difference between a great career move and a costly surprise.
THE EDITOR’S NOTE
A few thoughts from the field before we get into it…
I did not come into medical device the traditional way. I was working at Enterprise Rent-A-Car when a customer came in to pick up a car and mentioned he was in med device sales. I asked him about it. He explained what he did, what it looked like day to day, what the opportunity was. By the time he drove off the lot, I already knew I was going to find a way in.
My first job was with a small distributor selling absorbable pins and screws. Straight commission, no base. My first paycheck for a full month of work was $280.
That number grew over time as I learned the product, built relationships, and figured out how to actually sell in a clinical environment. But those early months taught me something that I think is worth passing along: how you get paid in this industry matters, and understanding it before you take a job is a lot better than figuring it out after.
There is a real difference between a straight commission 1099 role and a salaried W2 position with commission on top. Neither one is automatically better. A lot of it comes down to where you are in your career, how much financial runway you have, and honestly what kind of lifestyle you are comfortable with. Some people thrive in the commission-only structure from day one. Others need the stability of a base while they ramp. And sometimes what works at the beginning of your career is not what you want five years in.
That is what this issue is about: understanding the different compensation structures in medical device sales so you can make an informed decision, not just take the first offer that sounds good.
Glad you're here. Let's get into it.
Andy Knapik, Founder
The Modern Med Rep
INDUSTRY INTEL
What's moving in med device this week and why it matters
Five Things Shaping the Industry Right Now
→ Boston Scientific's $14.5B Penumbra deal closes
The largest medtech acquisition of 2026 positions BSc as a major player in thrombectomy. For reps, it signals continued consolidation and a growing premium on clinical complexity selling.
→ Danaher finalizes $9.9B Masimo acquisition
The deal closed in June and combines Masimo's pulse oximetry business with Danaher's Radiometer diagnostics unit. Another sign that patient monitoring and diagnostics are becoming strategic priorities.
→ Stryker cuts guidance after hip and knee slowdown
Q3 2026 revenue came in at $6.5B, up 7.7%, but hip sales fell 1% and knee sales grew just 1.1%. CEO Kevin Lobo said patients are delaying elective procedures due to higher insurance premiums and pre-authorization denials. Full-year guidance was cut from 8.3-9.3% growth to 6.5-7.0%. Stryker says it hasn't lost share to competitors. The market just slowed.
→ Medtronic adds two neuromodulation assets
Medtronic completed acquisitions of both CathWorks (AI-guided coronary assessment) and SPR Therapeutics (peripheral nerve stimulation for chronic pain) in the same quarter. Portfolio expansion continues at pace.
→ J&J / Smith & Nephew ortho mega-merger falls apart
Talks on a potential $34B combination of DePuy Synthes and Smith & Nephew broke down in October over one issue: who would run the company. J&J wanted a specific CEO candidate; Smith & Nephew's board held firm on their own. J&J is now leaning toward spinning DePuy Synthes out as a standalone company by mid-2027. For reps and job seekers, a spin-off of that scale will reshape the ortho sales landscape.
MARKET SPOTLIGHT
A deep dive into the segments, companies and technologies shaping the industry
What the Numbers Say and What They Don’t
The compensation conversation in medical device sales usually starts with a number someone heard at a networking event or read on Glassdoor. That number is almost always incomplete.
Here is a more honest look at how the money actually works.
THE RANGES YOU’LL SEE
Base salary across the industry runs roughly $50,000 to $110,000 depending on the category. Consumables and entry-level roles tend to land toward the lower end. Capital equipment and surgical implants sit higher. That base, by itself, does not tell you much about what you'll actually earn.
Total compensation is where it gets interesting. RepVue data puts median on-target earnings for experienced reps around $160,000. Top performers in high-acuity specialties, capital equipment, or surgical robotics can push well past $300,000. Those are real numbers, but they represent a specific combination of role, territory, and performance that not everyone lands in year one.
The figure to negotiate is not just the base. It's the plan: how commissions are calculated, when they pay out, and what happens if you come in above or below quota.
CAPITAL EQUIPMENT VS. IMPLANTS VS. CONSUMABLES
These three categories pay differently because they sell differently. The actual commission rates vary widely depending on whether you are in a direct W2 role or working through a distributor, so quoting specific percentages here would be misleading. What matters more is understanding how income flows in each category.
Capital equipment involves larger deal sizes and longer sales cycles. A single placement can generate significant income, but you may go months building toward that close. If your territory has few capital budget approvals in a given year, commission income can be lumpy regardless of how hard you work. The wins are bigger, but the timing is out of your control.
Surgical implants are driven by case volume. If your surgeons are busy and your product is on contract, income tends to be consistent and predictable. If procedure volume drops, whether because of an ASC conversion, a surgeon retiring, or a competitor winning a contract, you feel it quickly. The relationship between effort and income is more direct here than in capital.
Consumables are recurring. You are not hunting for a large one-time sale every quarter; you are building a base of accounts that reorder. The ceiling per transaction is lower, but the income tends to be steadier. For reps who want more predictability, this structure can feel more manageable, especially early in a career.
DIRECT VS. DISTRIBUTOR: TWO DIFFERENT ECONOMIC REALITIES
Direct positions are employment with the manufacturer. You get a W2, a base salary, a company car or car allowance, benefits, and a defined commission structure. The upside is predictability, stability, and institutional support. The downside is that commission plans at large manufacturers often cap out or include accelerators that require significant above-quota performance to access.
Distributor roles operate differently. The rep is often a 1099 independent contractor or an employee of the distributor organization rather than the manufacturer. Benefits may be limited or absent. The base is often lower. But commission structures at distributors frequently run richer, and some have no hard cap. Reps who build strong surgeon relationships and high-volume territories in a distributor model can out-earn their direct counterparts significantly.
Neither model is objectively better. The right answer depends on where you are in your career, how much risk you can absorb, and how much of your income you want tied to variables outside your control.
WHAT “UNCAPPED EARNING POTENTIAL” ACTUALLY MEANS
Every job posting that says this is technically telling the truth. It means the commission plan does not have a stated maximum.
What it does not tell you: how many reps in that territory actually hit the numbers implied in the on-target earnings figure, what the territory looks like in terms of existing accounts and growth potential, or whether the product is in a competitive position to win business.
Before taking a role based on earning potential, ask to see the last two to three years of territory results for the person who held it before you. Ask what percentage of the sales force hit or exceeded quota last year. Those questions give you real signal.
CAREER OPPORTUNITIES
Where the jobs are, what’s paying, and how to position yourself to get there
Reading A Comp Plan Before You Sign It
Industry Foundation: How Sales Territories Are Structured
In medical device, a territory is your business. It defines which accounts you can sell to, which hospitals and surgical centers fall under your responsibility, and how your quota is set. Territories vary widely in their potential: some are dense urban markets with high case volume, some are sprawling rural regions where you drive three hours between stops.
When evaluating a territory, look at account penetration (what percentage of potential accounts are already customers), competitive landscape (who else is selling into these accounts), procedure volume trends, and whether the previous rep left on good terms. A great product in a neglected territory can be an opportunity. A great product in a burned territory can be a long climb.
Want to understand more about how the industry is structured? Visit themodernmedrep.com for more.
A compensation plan is a document. Like any document, most people scan it rather than read it. That is a mistake that can cost real money.
Here is what to look for.
DRAW VS. SALARY
Some entry-level and associate roles offer a draw against commissions rather than a true base salary. A draw means the company advances you money each month, which is then recovered from future commissions. If your commissions don't cover the draw, you may owe it back. Understand whether your draw is recoverable or non-recoverable before signing.
QUOTA STRUCTURE AND TERRITORY ASSIGNMENT
A quota is not just a number. It is a number in the context of a territory. Understand how quota is set and how it changes year to year. Reps who consistently beat quota sometimes find their target raised faster than their commission income can keep pace. Ask how quota is typically adjusted and what the history looks like in that territory.
ACCELERATORS AND MULTIPLIERS
Most commission plans include accelerators that kick in above 100% of quota. A plan might pay 5% commission up to quota and 8% on everything above it. These can significantly change your income at the high end. Understand where the thresholds are and what the multipliers look like.
CLAWBACKS
Some plans include clawback provisions: if a customer cancels or returns product within a certain window, the commission is deducted from future pay. This is more common in capital equipment and software. It is not a dealbreaker, but you should know it's there.
W2 VS. 1099: THE TAX AND BENEFITS FEATURE
A W2 role means the employer handles payroll taxes, often provides benefits, and you receive a standard employee relationship. A 1099 role means you are responsible for your own taxes, including self-employment tax, which currently runs about 15.3% on top of income tax. If you move from a W2 to a 1099 role and your gross income stays the same, your net take-home drops meaningfully unless the commission rate accounts for it.
If you're evaluating a 1099 distributor role, factor in what you're giving up on the benefits side and what you're gaining on the commission side. Then run the math honestly.
THE MED INSIDER
One thing every med device professional should know this week
Practical Moves for This Week
ASK THE COMP QUESTIONS BEFORE THE OFFER
Once you have an offer in hand, your leverage shifts. The best time to understand the compensation structure is during the interview process, before anyone has made a commitment. Ask: how is commission calculated? What percentage of reps hit quota? What does the territory look like historically? These are not unusual questions. Any hiring manager worth working for will respect them.
GET THE COMP PLAN IN WRITING
Verbal descriptions of compensation plans are not contracts. Before you give notice at your current role or decline other opportunities, make sure you have seen the actual written plan. Things that were described one way in conversation sometimes read differently on paper.
TALK TO REPS WHO DO THE JOB
The most reliable source of information about a compensation plan is someone who actually works under it. If you're seriously considering a role, find reps at that company, ideally in similar territories, and ask what the real experience has been. RepVue is a useful starting point. Direct conversations are better.
UNDERSTAND WHAT YOUR FIRST YEAR WILL LOOK LIKE
Most medtech comp plans have a ramp period, typically three to six months, where a new rep is protected by a higher draw or a guaranteed floor. Understand exactly what that looks like, when it ends, and what's expected of you at the end of it. The transition from ramp to full plan is where a lot of new reps get surprised.
FROM THE FIELD
What I Wish Someone Had Told Me About the Money
The scenario: You're a rep with four years in pharmaceutical sales, solid income, good benefits, company car. You've been tracking medtech for a while and you're seriously considering the move. You've been told the earning potential is better. What you haven't been told is everything else.
“I thought I was stepping into a pay raise. What I actually stepping into was a different business model.”
Here's what often surprises reps making the transition from pharma or other industries:
The base salary in your first medtech role may be lower than what you're earning now. Especially in a distributor role or an associate position, the base can feel like a step backward. The promise is in the upside, but the upside is not guaranteed and does not arrive on day one.
Benefits at a distributor may be thin or nonexistent. If you've had an employer covering most of your health insurance, the cost of buying your own plan can be a significant hit to your real take-home.
The ramp period is real, but it ends. That protected draw gives you time to build a book, but the clock is ticking. Reps who come in expecting to be fully ramped at month four and find themselves still building at month seven feel real financial stress.
"The reps who do best are the ones who go in with their eyes open. They ask the questions. They run the numbers. They don't take the OTE figure at face value."
Three things worth doing before you make the move:
First, build a 12-month financial model. Take the base salary, subtract taxes and benefits you'll need to cover, and figure out what your monthly floor looks like during ramp. Make sure that number is livable without commissions.
Second, ask the hiring manager point-blank: what did the last rep in this territory earn in year one and year two? If they deflect, that's information.
Third, talk to reps outside the interview process. Find someone on LinkedIn who works at the company in a similar role. Buy them coffee. The conversation is worth more than anything the job posting says.
The income potential in medical device is real. So is the work it takes to get there. Both things are true, and both deserve honest consideration before you sign.
Have a question? Reply to this email. The best ones make it into the next issue.
QUOTE OF THE WEEK
“Beware of little expenses. A small leak will sink a great ship.”
- Benjamin Franklin
